Opportunity Information: Apply for PA 08 219
Apply for PA 08 219
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Drug Abuse Prevention Intervention Research (R03)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Dec 5, 2008 and posted on Jul 28, 2008.
- Applicants must submit their applications by Sep 7, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Public and State controlled institutions of higher education Small businesses Special district governments For profit organizations other than small businesses City or township governments Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Independent school districts Private institutions of higher education County governments Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Drug Abuse Prevention Intervention Research (R03) opportunity (Funding Opportunity Number PA-08-219) is a National Institutes of Health discretionary grant program designed to move the science of drug abuse prevention and drug-related HIV prevention forward through smaller, early-stage studies. The central goal is to support pilot and feasibility research that can generate initial evidence, refine intervention concepts, and lay the groundwork for larger prevention trials or broader implementation work. In practical terms, the opportunity is aimed at helping researchers explore promising ideas quickly and with limited resources, especially ideas that could ultimately contribute to population-level reductions in drug use, drug dependence, and the wide range of harms that often travel with substance use.
The research scope is broad but organized around four major themes. First, it encourages the development of novel prevention approaches, meaning entirely new strategies, frameworks, or tools that could prevent drug use initiation, escalation, or related harms. Second, it supports testing of novel interventions as well as adapted interventions, which includes taking an approach that has worked in one setting or population and carefully modifying it to fit a different context, culture, age group, delivery system, or risk environment. Third, it prioritizes studies that clarify how evidence-based interventions are selected, adopted, adapted, implemented, sustained over time, and financed in real-world settings. This emphasis reflects the reality that even well-supported interventions can fail to produce impact if they are not implemented well, cannot be maintained, or are not financially viable for the organizations expected to deliver them. Fourth, it invites the development of new methodologies for prevention research design and analysis, such as improved measurement strategies, analytic methods, recruitment and retention approaches, or study designs better suited to prevention questions and community settings.
The public health outcomes this FOA is trying to influence go beyond drug use alone. It explicitly includes drug-related problems such as interpersonal violence, criminal involvement, and productivity losses, as well as drug-related illness. Drug-related illness is framed to include comorbid mental health problems and infectious diseases linked to drug use or related risk behavior, specifically calling out HIV as well as hepatitis B and hepatitis C. The overall direction is prevention science that can plausibly translate to measurable, real-world reductions in harm at scale, not just individual-level behavior change in controlled environments.
This funding opportunity uses the NIH Small Research Grant (R03) mechanism, which is intended for small, self-contained projects that can be completed in a relatively short timeframe and with limited funds compared to larger NIH awards. The FOA notes several project types that fit well under the R03 umbrella, including pilot and feasibility studies, secondary analyses of existing datasets, small stand-alone research projects, and work focused on developing research methods or new research technologies. Importantly, PA-08-219 runs in parallel with two other NIH announcements of the same scientific scope that use different mechanisms: an R01 version (PA-08-217) for larger, full-scale research projects and an R21 version (PA-08-218) for exploratory and developmental work. Applicants whose projects are too large for an R03 are implicitly being guided to consider those companion announcements instead.
In terms of funding levels and award counts, the FOA does not commit to a fixed number of awards or a single standard budget size. Instead, it states that the size and duration of each award will vary depending on the proposed research, and that the total number of awards and total funds awarded will depend on factors such as the mechanisms, the quality of the applications, proposed project duration, and the requested costs. The program is listed under CFDA 93.279 (Drug Abuse and Addiction Research Programs), does not require cost sharing or matching, and is administered by NIH.
Eligibility is intentionally expansive and includes many kinds of organizations that might be positioned to conduct prevention research or partner in it. Eligible applicants include public and private institutions of higher education, nonprofits (both 501(c)(3) and certain non-501(c)(3) entities), small businesses and other for-profit organizations (including those that are not small businesses), local and state government entities, special district governments, independent school districts, public housing authorities/Indian housing authorities, and a range of tribal organizations and governments (including federally recognized tribal governments and other tribal entities). The FOA also highlights additional eligible groups such as faith-based and community-based organizations, U.S. territories or possessions, regional organizations, and a number of institution types that serve specific populations, including HBCUs, Hispanic-serving institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian-serving institutions, and eligible federal agencies. It also indicates that non-U.S. entities (foreign organizations) may be eligible, which can be relevant for prevention research in international or cross-national contexts.
Administratively, the opportunity was posted July 28, 2008, with a closing date of September 7, 2011, and an archive date of October 8, 2011, meaning it is no longer active for new submissions under those dates. The full announcement was hosted through the NIH grants guide, and the provided contact for access or linking problems is the NIH Office of Extramural Research webmaster.
Frequently Asked Questions (FAQs): Drug Abuse Prevention Intervention Research (R03) - PA-08-219
What is PA-08-219?
PA-08-219 is an NIH discretionary grant funding opportunity titled Drug Abuse Prevention Intervention Research (R03). It is designed to advance the science of drug abuse prevention and drug-related HIV prevention through smaller, early-stage studies.
What is the main goal of this funding opportunity?
The central goal is to support pilot and feasibility research that can generate initial evidence, refine prevention intervention concepts, and create a foundation for larger prevention trials or broader implementation efforts.
What types of research does this FOA support?
This FOA supports smaller, early-stage projects intended to help researchers test promising ideas quickly with limited resources, especially work with the potential to contribute to population-level reductions in drug use, dependence, and related harms.
How is the research scope organized?
The scope is broad but organized around four themes:
- Development of novel prevention approaches (new strategies, frameworks, or tools).
- Testing novel or adapted interventions (including careful adaptation to new settings, populations, cultures, ages, delivery systems, or risk environments).
- Understanding real-world use of evidence-based interventions, including how they are selected, adopted, adapted, implemented, sustained, and financed.
- New methodologies for prevention research, such as improved measurement, analytic methods, recruitment and retention approaches, and prevention-suited study designs.
What does “novel prevention approaches” mean in this announcement?
It refers to entirely new strategies, frameworks, or tools intended to prevent drug use initiation, escalation, or related harms.
Are adapted interventions allowed, or only brand-new interventions?
Adapted interventions are explicitly included. This can involve taking an approach that worked in one setting or population and modifying it to fit a different context (such as a different culture, age group, delivery system, or risk environment).
Does the FOA include implementation-focused research?
Yes. One of the priority areas is research that clarifies how evidence-based interventions are selected, adopted, adapted, implemented, sustained over time, and financed in real-world settings.
Why does this FOA emphasize sustainability and financing?
The FOA reflects that even evidence-based interventions may fail to produce meaningful impact if they are not implemented well, cannot be maintained over time, or are not financially viable for organizations expected to deliver them.
Does the opportunity support prevention research methods development?
Yes. It invites the development of new methodologies for prevention research design and analysis, including improved measurement strategies, analytic methods, recruitment and retention approaches, and study designs suited to prevention questions and community settings.
What outcomes is the FOA trying to influence?
The FOA targets outcomes beyond drug use alone. It includes reductions in drug use and drug dependence, as well as drug-related harms such as interpersonal violence, criminal involvement, productivity losses, and drug-related illness.
What is included under “drug-related illness” in this FOA?
Drug-related illness is framed to include comorbid mental health problems and infectious diseases linked to drug use or related risk behavior, specifically including HIV as well as hepatitis B and hepatitis C.
Is this a clinical trial grant?
The FOA is geared toward smaller, early-stage studies (pilot and feasibility work) intended to lay the groundwork for larger prevention trials or broader implementation research. The announcement emphasizes building initial evidence rather than funding large, full-scale trials under this mechanism.
What grant mechanism does PA-08-219 use?
PA-08-219 uses the NIH Small Research Grant (R03) mechanism, intended for small, self-contained projects that can be completed in a relatively short timeframe with limited funds compared to larger NIH awards.
What kinds of projects are a good fit for an R03 under this FOA?
The FOA identifies several project types that can fit under the R03 mechanism, including:
- Pilot and feasibility studies
- Secondary analyses of existing datasets
- Small stand-alone research projects
- Development of research methods or new research technologies
Are there related opportunities if an R03 is too small for my project?
Yes. This FOA runs in parallel with two companion announcements with the same scientific scope but different mechanisms:
- R01 version: PA-08-217 (larger, full-scale research projects)
- R21 version: PA-08-218 (exploratory and developmental work)
If a project is too large for an R03, the FOA implicitly points applicants to consider these companion announcements.
How much funding is available and how many awards will be made?
The FOA does not commit to a fixed number of awards or a standard budget size. It states that award size and duration will vary based on the proposed research, and total awards and total funds will depend on factors such as the mechanism, application quality, project duration, and requested costs.
Is cost sharing or matching required?
No. The FOA states that cost sharing or matching is not required.
What is the CFDA number for this program?
The program is listed under CFDA 93.279 (Drug Abuse and Addiction Research Programs).
Who administers this funding opportunity?
The opportunity is administered by the National Institutes of Health (NIH).
What organizations are eligible to apply?
Eligibility is broad. The FOA lists eligible applicants that include:
- Public and private institutions of higher education
- Nonprofits (501(c)(3) and certain non-501(c)(3) entities)
- Small businesses and other for-profit organizations (including those that are not small businesses)
- Local and state government entities
- Special district governments
- Independent school districts
- Public housing authorities / Indian housing authorities
- Tribal governments (federally recognized) and other tribal organizations
- U.S. territories or possessions
- Regional organizations
- Eligible federal agencies
Are faith-based and community-based organizations eligible?
Yes. The FOA highlights faith-based and community-based organizations as eligible applicants.
Are institutions serving specific populations called out as eligible?
Yes. The FOA indicates eligibility includes institutions such as HBCUs, Hispanic-serving institutions, Tribally Controlled Colleges and Universities, Alaska Native-serving institutions, and Native Hawaiian-serving institutions.
Are non-U.S. (foreign) organizations eligible to apply?
Yes. The FOA indicates that non-U.S. entities (foreign organizations) may be eligible, which may be relevant for international or cross-national prevention research contexts.
When was this opportunity posted, and is it still open?
The opportunity was posted on July 28, 2008, had a closing date of September 7, 2011, and an archive date of October 8, 2011. Based on these dates, it is no longer active for new submissions under the listed schedule.
Where was the full announcement hosted?
The full announcement was hosted through the NIH grants guide.
Who is the listed contact for access or link problems?
The provided contact for access or linking problems is the NIH Office of Extramural Research webmaster.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: Investigational Nutrigenetic Studies for Cancer Prevention (R01)
Previous opportunity: Drug Abuse Prevention Intervention Research (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 08 219
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 08 219) also looked into and applied for these:
| Funding Opportunity |
|---|
| Investigational Nutrigenetic Studies for Cancer Prevention (R01) Apply for PA 08 220 Funding Number: PA 08 220 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Investigational Nutrigenetic Studies for Cancer Prevention (R21) Apply for PA 08 221 Funding Number: PA 08 221 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Etiology, Prevention, and Treatment of Hepatocellular Carcinoma(R21) Apply for PA 08 244 Funding Number: PA 08 244 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Central Nervous System Intersections of Drug Addiction, Chronic Pain and Analgesia (R03) Apply for RFA DA 09 019 Funding Number: RFA DA 09 019 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Central Nervous System Intersections of Drug Addiction, Chronic Pain and Analgesia (R01) Apply for RFA DA 09 017 Funding Number: RFA DA 09 017 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Physical Science Oncology Centers (U54) Apply for RFA CA 09 009 Funding Number: RFA CA 09 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $2,250,000 |
| NINR Mentored Research Scientist Development Award for Underrepresented or Disadvantaged Investigators (K01) Apply for PAR 05 135 Funding Number: PAR 05 135 Agency: National Institutes of Health Category: Education Health Funding Amount: $20,000 |
| NCI Transition Career Development Award to Promote Diversity (K22) Apply for PAR 08 047 Funding Number: PAR 08 047 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NINR Career Transition Award (K22) Apply for PAR 08 148 Funding Number: PAR 08 148 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research on the Cognitive Sequelae of Parkinsons Disease (R01) Apply for PA 09 033 Funding Number: PA 09 033 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Established Investigator Award in Cancer Prevention and Control Apply for PAR 05 145 Funding Number: PAR 05 145 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI Mentored Career Development Award to Promote Diversity (K01) Apply for PAR 06 220 Funding Number: PAR 06 220 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI Mentored Clinical Scientist Award to Promote Diversity (K08) Apply for PAR 06 221 Funding Number: PAR 06 221 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Mentored Patient Oriented Research Award to Promote Diversity (K23) Apply for PAR 06 222 Funding Number: PAR 06 222 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Building Translational Research in Integrative Behavioral Science (R24) Apply for PAR 06 357 Funding Number: PAR 06 357 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| Cancer Prevention, Control, Behavioral, and Population Sciences Career Development Award (K07) Apply for PAR 06 381 Funding Number: PAR 06 381 Agency: National Institutes of Health Category: Education Health Funding Amount: $105,000 |
| Paul Calabresi Career Development Award For Clinical Oncology (K12) Apply for PAR 06 449 Funding Number: PAR 06 449 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| The NCI Transition Career Development Award (K22) Apply for PAR 06 455 Funding Number: PAR 06 455 Agency: National Institutes of Health Category: Education Health Funding Amount: $125,000 |
| Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows (F31) Apply for PA 07 002 Funding Number: PA 07 002 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Feasibility Studies for Collaborative Interaction for Minority Institution/Cancer Center Partnership (P20) Apply for PAR 07 230 Funding Number: PAR 07 230 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 08 219", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.